Imunon Inc (IMNN) - Net Assets

Latest as of March 2026: $3.36 Million USD

Based on the latest financial reports, Imunon Inc (IMNN) has net assets worth $3.36 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.02 Million) and total liabilities ($4.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IMNN intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $3.36 Million
% of Total Assets 41.9%
Annual Growth Rate 0.15%
5-Year Change -87.34%
10-Year Change 5.0%
Growth Volatility 239.47

Imunon Inc - Net Assets Trend (1996–2025)

This chart illustrates how Imunon Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Imunon Inc fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Imunon Inc (1996–2025)

The table below shows the annual net assets of Imunon Inc from 1996 to 2025. For live valuation and market cap data, see market cap of Imunon Inc.

Year Net Assets Change
2025-12-31 $7.06 Million +66.39%
2024-12-31 $4.24 Million -68.30%
2023-12-31 $13.39 Million -54.35%
2022-12-31 $29.33 Million -47.44%
2021-12-31 $55.80 Million +199.80%
2020-12-31 $18.61 Million +27.83%
2019-12-31 $14.56 Million -30.21%
2018-12-31 $20.86 Million -21.88%
2017-12-31 $26.70 Million +297.04%
2016-12-31 $6.73 Million -67.01%
2015-12-31 $20.39 Million -37.90%
2014-12-31 $32.83 Million +4.13%
2013-12-31 $31.52 Million +163.54%
2012-12-31 $11.96 Million -54.33%
2011-12-31 $26.19 Million +672.47%
2010-12-31 $-4.58 Million -145.59%
2009-12-31 $10.04 Million -49.13%
2008-12-31 $19.73 Million -35.64%
2007-12-31 $30.65 Million +1057.60%
2006-12-31 $-3.20 Million -193.44%
2005-12-31 $3.43 Million -71.38%
2004-12-31 $11.97 Million -11.02%
2003-12-31 $13.45 Million +787.11%
2002-12-31 $1.52 Million -43.19%
2001-12-31 $2.67 Million -69.41%
2000-12-31 $8.73 Million +772.64%
1999-12-31 $1.00 Million +154.02%
1998-12-31 $-1.85 Million +24.77%
1997-12-31 $-2.46 Million -136.42%
1996-12-31 $6.76 Million --

Equity Component Analysis

This analysis shows how different components contribute to Imunon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 40908636700.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $34.00K 0.48%
Other Components $428.33 Million 6065.22%
Total Equity $7.06 Million 100.00%

Imunon Inc Competitors by Market Cap

The table below lists competitors of Imunon Inc ranked by their market capitalization.

Company Market Cap
T4F Entretenimento S.A
SA:SHOW3
 $7.82 Million
Augros Cosmetic Packaging SA
PA:AUGR
 $7.82 Million
Kibo Energy PLC
JSE:KBO
 $7.82 Million
UET United Electronic Technology AG
XETRA:CFC
 $7.83 Million
Ho Hup Construction Company
KLSE:5169
 $7.81 Million
E Media Holdings Ltd
JSE:EMH
 $7.79 Million
Morella Corporation Ltd
AU:1MC
 $7.79 Million
Grolleau SAS
PA:ALGRO
 $7.79 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Imunon Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 4,244,298 to 7,062,000, a change of 2,817,702 (66.4%).
  • Net loss of 14,495,000 reduced equity.
  • Dividend payments of 10,277 reduced retained earnings.
  • New share issuances of 13,628,070 increased equity.
  • Other factors increased equity by 3,694,909.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-14.49 Million -205.25%
Dividends Paid $10.28K -0.15%
Share Issuances $13.63 Million +192.98%
Other Changes $3.69 Million +52.32%
Total Change $- 66.39%

Book Value vs Market Value Analysis

This analysis compares Imunon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.56x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.00x to 0.56x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-12-31 $56710.10 $1.86 x
1997-12-31 $-18345.23 $1.86 x
1998-12-31 $-1275.81 $1.86 x
1999-12-31 $4609.36 $1.86 x
2000-12-31 $31077.03 $1.86 x
2001-12-31 $7816.16 $1.86 x
2002-12-31 $3677.32 $1.86 x
2003-12-31 $25039.54 $1.86 x
2004-12-31 $1068.92 $1.86 x
2005-12-31 $3936.85 $1.86 x
2006-12-31 $-3677.50 $1.86 x
2007-12-31 $35202.44 $1.86 x
2008-12-31 $23958.11 $1.86 x
2009-12-31 $11609.59 $1.86 x
2010-12-31 $-4557.30 $1.86 x
2011-12-31 $15435.22 $1.86 x
2012-12-31 $4238.79 $1.86 x
2013-12-31 $6377.47 $1.86 x
2014-12-31 $4868.06 $1.86 x
2015-12-31 $2560.05 $1.86 x
2016-12-31 $709.77 $1.86 x
2017-12-31 $685.03 $1.86 x
2018-12-31 $232.13 $1.86 x
2019-12-31 $130.47 $1.86 x
2020-12-31 $113.93 $1.86 x
2021-12-31 $2011.61 $1.86 x
2022-12-31 $53.55 $1.86 x
2023-12-31 $19.31 $1.86 x
2024-12-31 $4.81 $1.86 x
2025-12-31 $3.33 $1.86 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Imunon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -205.25%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.74x
  • Recent ROE (-205.25%) is below the historical average (-131.82%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 -28.62% -2612.59% 0.01x 1.38x $-2.61 Million
1997 0.00% -2516.88% 0.15x 0.00x $-2.81 Million
1998 0.00% -2411.55% 0.53x 0.00x $-4.02 Million
1999 -240.00% -2400.00% 0.06x 1.60x $-2.50 Million
2000 -52.11% -132959.50% 0.00x 1.04x $-5.42 Million
2001 -259.37% 0.00% 0.00x 1.11x $-7.19 Million
2002 -643.00% 0.00% 0.00x 1.51x $-9.90 Million
2003 -98.67% 0.00% 0.00x 1.07x $-14.62 Million
2004 -116.83% -558.01% 0.15x 1.42x $-15.18 Million
2005 -253.55% -70.50% 0.77x 4.64x $-9.03 Million
2006 0.00% -67.41% 0.59x 0.00x $-7.26 Million
2007 115.33% 0.00% 0.00x 1.27x $32.28 Million
2008 -59.75% -471.45% 0.11x 1.20x $-13.76 Million
2009 -151.39% 0.00% 0.00x 1.48x $-16.20 Million
2010 0.00% 0.00% 0.00x 0.00x $-18.36 Million
2011 -88.66% -1161.13% 0.06x 1.25x $-25.84 Million
2012 -222.11% 0.00% 0.00x 2.12x $-27.76 Million
2013 -26.17% -1650.27% 0.01x 1.45x $-11.40 Million
2014 -77.67% -5098.85% 0.01x 2.03x $-28.78 Million
2015 -110.18% -4492.22% 0.01x 2.41x $-24.50 Million
2016 -327.90% -4410.75% 0.02x 4.59x $-22.73 Million
2017 -76.40% -4080.44% 0.01x 1.78x $-23.07 Million
2018 -56.96% -2376.67% 0.01x 2.25x $-13.97 Million
2019 -115.75% -3370.31% 0.01x 2.63x $-18.31 Million
2020 -115.43% -4296.71% 0.01x 2.02x $-23.34 Million
2021 -37.22% -4153.85% 0.01x 1.33x $-26.35 Million
2022 -122.40% -7179.65% 0.01x 1.50x $-38.83 Million
2023 -145.77% -15611.98% 0.01x 1.64x $-20.85 Million
2024 -438.71% 0.00% 0.00x 2.29x $-19.04 Million
2025 -205.25% 0.00% 0.00x 1.74x $-15.20 Million

Industry Comparison

This section compares Imunon Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $155,285,360
  • Average return on equity (ROE) among peers: -101.11%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Imunon Inc (IMNN) $3.36 Million -28.62% 1.39x $7.82 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $83.17 Million
Abcellera Biologics Inc (ABCL) $830.51 Million 14.32% 0.21x $1.61 Billion
Abeona Therapeutics Inc (ABEO) $-26.99 Million 0.00% 0.00x $321.39 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $155.29 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $2.00 Million
Absci Corp (ABSI) $179.13 Million -57.56% 0.19x $1.01 Billion
Arbutus Biopharma Corp (ABUS) $182.50 Million -46.25% 0.30x $831.63 Million
ABVC Biopharma Inc (ABVC) $4.59 Million -357.76% 1.38x $35.10 Million
Abivax SA American Depositary Shares (ABVX) $33.94 Million -14.97% 0.12x $7.98 Billion
ACADIA Pharmaceuticals Inc (ACAD) $113.93 Million -49.49% 0.18x $3.66 Billion

About Imunon Inc

NASDAQ:IMNN USA Biotechnology
Market Cap
$7.82 Million
Market Cap Rank
#27633 Global
#5632 in USA
Share Price
$1.86
Change (1 day)
-1.06%
52-Week Range
$0.49 - $9.20
All Time High
$474.60
Categories
Companies in USA Biotechnology
About

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more